Euglycemic Ketoacidosis Following Coadministration of an SGLT2 Inhibitor and Tirzepatide
Open Access
- 10 February 2025
- journal article
- case report
- Published by The Endocrine Society in JCEM Case Reports
- Vol. 3 (3) , luaf028
Abstract
Euglycemic ketoacidosis (EKA) is a life-threatening condition characterized by ketone production leading to systemic acidosis, dehydration, and end-organ damage. It presents similarly to diabetic ketoacidosis, except that patients have normal to slightly elevated blood glucose levels. EKA is an increasingly recognized complication of sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists. Recently the novel dual GLP-1 and glucose-dependent insulinotropic polypeptide receptor agonist tirzepatide was approved for treatment of diabetes and weight loss. Here, we describe a unique case in which a patient placed on both an SGLT2 inhibitor and tirzepatide to treat type 2 diabetes was admitted to the intensive care unit (ICU) for EKA. To our knowledge, this is the first case detailing a patient developing this serious condition after starting tirzepatide for diabetes. The patient required treatment and monitoring in an ICU to make a full recovery. As tirzepatide is a relatively new medication whose side effect profile has yet to be fully characterized, clinicians should be aware of this rare yet potentially fatal complication.Keywords
Funding Information
- HCA Healthcare
This publication has 18 references indexed in Scilit:
- Change in pharmacodynamic variables following once‐weekly tirzepatide treatment versus dulaglutide in Japanese patients with type 2 diabetes ( SURPASS J‐mono substudy)Diabetes, Obesity and Metabolism, 2022
- Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trialThe Lancet Diabetes & Endocrinology, 2022
- Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trialThe Lancet Diabetes & Endocrinology, 2022
- Tirzepatide Once Weekly for the Treatment of ObesityNew England Journal of Medicine, 2022
- National Trends in Use of Sodium‐Glucose Cotransporter‐2 Inhibitors and Glucagon‐like Peptide‐1 Receptor Agonists by Cardiologists and Other Specialties, 2015 to 2020Journal of the American Heart Association, 2022
- Comparative Safety of Sodium–Glucose Cotransporter 2 Inhibitors Versus Dipeptidyl Peptidase 4 Inhibitors and Sulfonylureas on the Risk of Diabetic KetoacidosisDiabetes Care, 2022
- Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 DiabetesJAMA, 2022
- Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trialThe Lancet, 2021
- Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trialThe Lancet, 2021
- Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort studyBMJ, 2018